Finance

Lists
Q3 2026 earnings • released • EPS met 0.00% • Revenue beat +13.90%
See results
ADCT:NYSE
Adc Therapeutics Ltd
$1.51
-9.58%
(-0.16) 1D
$1.51
0.00% (0.00)
After hours
Closed: Nov 10, 4:00:05 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ADCT...
Open
$1.62
High
$1.73
Low
$1.48
Mkt. cap
192.78M
Avg. vol.
1.58M
Volume
1.31M
52-wk high
$4.98
52-wk low
$0.78
EPS
-$0.73
Beta
1.82
Shares outstanding
127.67M
No. of employees
191
Open
$1.62
High
$1.73
Low
$1.48
Mkt. cap
192.78M
Avg. vol.
1.58M
Volume
1.31M
52-wk high
$4.98
52-wk low
$0.78
EPS
-$0.73
Beta
1.82
Shares outstanding
127.67M
No. of employees
191
News stories
From web sources and news partners
About Adc Therapeutics Ltd
CEO-
Employees191
Founded2011
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteadctherapeutics.com
Analyst ratings
Based on 2 analysts giving stock ratings to ADCT in the past 3 months
Buy
Buy
1
Hold
1
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for ADCT in the last 3 months.
Highest
Current $1.51
$5.00 (+231.13%)
Average
$3.50 (+131.79%)
Lowest
$2.00 (+32.45%)
Analyst
Recommendation
Action
Price target
Projected
Date
Leonid Timashev
RBC Capital
Hold
Maintained
$2.00
+32.5%
11/09/2026
Michael Schmidt
Guggenheim
Buy
Reiterated
$5.00
+231.1%
08/14/2026
Robert Burns
H.C. Wainwright
Hold
Downgraded
-
-
06/08/2026
Sudan Loganathan
Stephens
Buy
Reiterated
$5.00
+231.1%
06/04/2026
Last report
Nov 9, 2026
Fiscal period
Q3 2026
-$0.06 / -
0.00%miss
Revenue / Est. (USD)
21.72M / 19.07M
+13.90%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
16.43M
23.06M
20.85M
19.25M
Cost of goods sold
28.00M
17.60M
23.49M
19.72M
Cost of revenue
28.00M
17.60M
23.49M
19.72M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
19.01M
21.44M
22.60M
22.27M
Operating expense
19.01M
21.44M
22.60M
22.27M
Total operating expenses
47.02M
39.04M
46.10M
41.99M
Operating income
-30.59M
-15.98M
-25.24M
-22.74M
Other non operating income
587.00K
21.84M
2.30M
20.66M
EBT including unusual items
-40.97M
-6.81M
-32.97M
-16.56M
EBT excluding unusual items
-40.59M
-4.88M
-32.97M
-13.89M
Income tax expense
-
-404.00K
-
-
Effective tax rate
-
5.93%
-
-
Other operating expenses
-
-
-
-
Net income
-40.97M
-6.41M
-32.97M
-16.56M
Net profit margin
-249.38%
-27.80%
-158.11%
-86.06%
Earnings per share
-
-
-
-
Interest and investment income
2.47M
2.35M
1.99M
1.82M
Interest expense
-13.39M
-13.01M
-12.35M
-13.51M
Net interest expenses
-10.92M
-10.66M
-10.36M
-11.69M
Depreciation and amortization charges
-
-
-
-
EBITDA
-30.59M
-15.98M
-25.07M
-22.56M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps